Summit Therapeutics PLC says c-difficile trial slowed by coronavirus pandemic disruption
US infectious diseases company BARDA is supporting to fund the trial with a grant truly worth up to $72.5mln. (NASDAQ:SMMT)...
US infectious diseases company BARDA is supporting to fund the trial with a grant truly worth up to $72.5mln. (NASDAQ:SMMT)...